Drug Profile

Chimeric antigen receptor T cell therapy - Shanghai Unicar-Therapy Bio-medicine Technology

Latest Information Update: 28 Jan 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Shanghai Unicar-Therapy Bio-medicine Technology
Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
Mechanism of Action Gene silencing; Immunologic cytotoxicity; T lymphocyte replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

28 Jan 2024 No recent reports of development identified for preclinical development in Multiple-myeloma in China (Parenteral)
27 Dec 2019 Shanghai Unicar-Therapy Bio-medicine Technology plans a phase 0 trial for Multiple myeloma (Second-line therapy or greater, In adults, In the elderly) in China (ChiCTR1900028573)
01 Dec 2019 Preclinical trials in Multiple myeloma in China (Parenteral), before December 2019

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com